Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer

Figures

• 

  Figure 1. The results of GSEA analysis. (A) The heatmap of GSEA enriched pathways among different treatment groups. (B) The pathway network of siAKT group. (C) The pathway network of R5020 group. (D) The pathway network of siAKT+R5020 group. The blue dots represent upregulated pathways and the red dots were downregulated pathways.

• 

  Figure 2. The results of DEGs among different groups. (A) The volcano plot of DEGs in R5020 group. (B) The volcano plot of DEGs in siAKT group. (C) The volcano plot of DEGs in siAKT+R5020 group. (D)The gene intersections among different groups.

• 

  Figure 3. Construction of co-expression modules by WGCNA method. (A) The results of clustering analysis. (B) Analysis of the scale-free fit index for various soft-thresholding powers (β). (C) Analysis of the mean connectivity for various soft-thresholding powers. (D) Dendrogram of all DEGs clustered based on a dissimilarity measure (1-TOM). (E) Heatmap of the correlation between module eigengenes and sample groups of endometrial cancer.

• 

  Figure 4. Identification of hub genes associated with AKT. (A) The results of clustering analysis based on genes in brown module. (B) The PPI network of genes in brown module. (C) The box plot of differentially expressed patterns of six hub genes in endometrial cancer.

• 

  Figure 5. The expression and clinical significance of hub genes. (A) The expression heatmap of six genes in human cancers. (B) The survival K-M plot of six genes.

• 

  Figure 6. The validation analysis of AKT in TCGA database. (A) The expression heatmap of six genes and AKT in TCGA database. (B) The Pearson correlation coefficient of these genes and AKT. (C) The violin plot of these six genes in high-AKT and low-AKT groups.

• 

  Figure 7. Immunohistochemistry for AKT1, GTSE1, BIRC5, AURKA, PBK, KNSTRN, and PSMB10. Samples from cancer-adjacent endometrial tissue (N = 75) and endometrial cancer (N = 107). Cancer-adjacent endometrial tissue sample of weak immunostaining score for either AKT1 (A), GTSE1 (D), BIRC5 (G), AURKA (J), PBK (M), KNSTRN (P), and PSMB10 (S). Endometrial cancer sample of weak and strong immunostaining score for either AKT1 (B,C), GTSE1 (E,F), BIRC5 (H,I), AURKA (K,L), PBK (N,O), KNSTRN (Q,R), and PSMB10 (T,U). The expression for each gene were depicted in (V) slides (200 X, *p < 0.05, **p < 0.01).

• 

  Figure 8. Overall (OS) and progression-free survival (PFS) curves in endometrial cancer (N = 107) according to AKT1 (A,B), GTSE1 (C,D), BIRC5 (E,F), AURKA (G,H), PBK (I,J), KNSTRN (K,L), and PSMB10 (M,N) genes expression status.